AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics, w
UK biotech Autifony has signed an exclusive licensing deal with Jazz Pharmaceuticals, giving the Ireland-headquartered drugmaker global rights to a pair of ion channel tar
Researchers think they have worked out how neurons die off in Alzheimer's disease, a question that has gone unanswered for decades, opening new avenues for research and a
Astellas has been having some safety-related issues with its gene therapy programmes of late, but it shows no signs of lessened enthusiasm for the category – as a new alliance with US biote
Shares in VistaGen Therapeutics have plummeted after the company reported that its lead pherine nasal spray candidate failed the first of two phase 3 trials in social anxiety disorder (SAD)
Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson's disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl